By Lynda Williams, medwireNews Reporter
medwireNews: Primary mismatch repair deficiency (MMRD) in gliomas is underdiagnosed among people younger than 40 years old, say investigators who recommend assessment of the biomarker to help facilitate checkpoint inhibitor therapy.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit:© freshidea / Stock.adobe.com
.